 |
  |
|
23.01.2012 Sartorius Stedim
Biotech and Refine Technology Announce Cooperation |
|
|
Sartorius
Stedim Biotech
(SSB), a leading international
pharma supplier, and Refine Technology (Refine), the
developer and worldwide supplier to the biotech industry
of the ATF™ System, a best-in-class cell retention
device, will be collaborating on the development of a
robust platform for high-density cell cultivation.
|
|
 |
|
|
|
|
  |
|
23.01.2012 Active
Biotech's Prostate Cancer Project TASQ in Phase I
Combination Therapy Trial |
|
|
a Phase I
Investigator sponsored clinical trial,
led by Principal Investigator Dr.Andrew
Armstrong
at
Duke University Hospital, US, has been
announced for Active Biotech's (NASDAQ
OMX Nordic: ACTI) prostate cancer
project TASQ. The primary objective for
the CATCH trial (Cabazitaxel
(Jevtana)
And
Tasquinimod
in Men with
Castration-Resistant
Heavily pre-treated
... |
|
 |
|
|
|
|
  |
|
23.01.2012 MediGene
and EIP Eczacibasi Enter Agreement for the
Commercialization of Veregen® in Turkey
|
|
|
MediGene AG
(Frankfurt: MDG, Prime Standard)
(Frankfurt, Prime Standard, MDG)
has signed an exclusive license and supply agreement
with EIP Eczacibasi Ilac Pazarlama A.S. for the supply
and commercialization of Veregen®
ointment in Turkey. MediGene is entitled to successive
payments, due upon the achievement of set regulatory and
sales milestones, and will ... |
|
 |
|
|
|
|
  |
|
23.01.2012 MorphoSys
Strengthens Patent Position on MOR202 Program
|
|
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment;
TecDAX)
announced today that
the US Patent and Trademark Office (USPTO) has granted a
patent covering the Company's cancer compound
MOR202.
The new patent (US 8,088,896) covers MorphoSys's HuCAL
antibody against CD38 as well as pharmaceutical
compositions comprising the same, and has a scheduled
expiry date in 2028, not including any potential
regulatory extensions. |
|
 |
|
|
|
|
  |
|
20.02.2012 Cell Therapeutics,
Inc. Expects That the European Medicines Agency's (EMA)
Committee for Medicinal Products for Human Use (CHMP)
May Issue an Opinion on the Marketing Authorization
Application ("MAA") on Pixuvri™ in Mid-February |
|
|
Cell Therapeutics, Inc. ("CTI")
(NASDAQ and MTA: CTIC) announced today that, following
discussions with the European Medicines Agency's
("EMA") Committee for Medicinal Products for Human
Use ("CHMP"), the CHMP may issue an opinion on CTI's
Marketing Authorization Application ("MAA") for Pixuvri
in mid-February. In the interim, CTI will continue to
work ... |
|
 |
|
|
|
|
  |
|
18.01.2012 Sartorius Stedim
Biotech and G-Con Manufacturing Announce Global
Collaboration |
|
|
Sartorius
Stedim Biotech
and G-Con
have agreed to a global collaboration to offer highly
advanced and flexible production platforms for the
biopharmaceutical manufacturing industry. The new
product line will leverage G-Con Manufacturing’s novel
modular, mobile clean-room “pods” and Sartorius Stedim
Biotech’s well-established broad single-use and reusable
product portfolio... |
|
 |
|
|
|
|
  |
|
18.01.2012
vivoPharm Accesses New Cancer Models for US Market |
|
|
vivoPharm
Pty Ltd has entered into a partnership with
Experimental Pharmacology & Oncology
Berlin-Buch GmbH (EPO), one of Germanys
-leading preclinical oncology testing
company. |
|
 |
|
|
|
|
  |
|
18.01.2012 JSR Expands its
Biomedical Business by Investing in BIA Separations'
Unique Purification Technology |
|
|
JSR Corporation (Head Office:
Minato-Ku, Tokyo, President:
Mitsunobu Koshiba) and BIA
Separations (Head Office: Villach,
Managing Director and CEO: Aleš
Štrancar) announced that they have
entered a strategic partnership
which includes a minor equity
position by JSR on November 14th
2011. |
|
 |
|
|
|
|
|
 |
  |
Advance
Toward an Imaging Agent for Diagnosing
Alzheimer's Disease |
|
Scientists are reporting
development and initial laboratory tests
of an imaging agent that shows promise
for detecting the tell-tale signs of
Alzheimer's disease (AD) in the brain --
signs that now can't confirm a diagnosis
until after patients have died. Their
report appears in the journal ACS
Medicinal Chemistry Letters.

|
|
|
|
  |
A new way to
stimulate the immune system and fight
infection |
|
These new
data are an essential step towards
understanding the operation of these key
cells in the immune system, and they
could provide a new therapeutic approach
to fighting infection. They also suggest
that the operation of NK cells must be
precisely regulated to guarantee an
optimum immune reaction.

|
|
|
|
  |
Simpler
Times: Did an Earlier Genetic Molecule
Predate DNA and RNA? |
|
In the chemistry of the living
world, a pair of nucleic acids -- DNA
and RNA -- reign supreme. As carrier
molecules of the genetic code, they
provide all organisms with a mechanism
for faithfully reproducing themselves as
well as generating the myriad proteins
vital to living systems. Yet according
to John Chaput, a researcher at the
Center for Evolutionary Medicine and
Informatics, at Arizona State
University's Biodesign Institute®,
it may not always have been so.

|
|
|
|
  |
Essential
protein for the formation of new blood
vessels identified |
|
Angiogenic sprouting, the process
by which new blood vessels grow from
existing vessels, is a double-edged
sword. It enables the cardiovascular
system to develop in the embryo, and is
vital for tissue regeneration in adults.
But it also supplies growing tumors with
nutrients and oxygen.

|
|
|
|
  |
Anti-malaria
drug synthesised with the help of oxygen
and light |
|
The most effective anti-malaria
drug can now be produced inexpensively
and in large quantities. This means that
it will be possible to provide
medication for the 225 million malaria
patients in developing countries at an
affordable price. Researchers at the Max
Planck Institute of Colloids and
Interfaces in
...

|
|
|
|
Rare Chinese
white dolphin gets DNA bank |
|
There are about 2,500 Chinese white dolphins
in the Pearl River Delta region, the body of
water between Macau and Hong Kong, with the
majority of the mammals in Chinese waters
and the rest in Hong Kong.
But experts say their
number has dropped significantly in the past
few years due to overfishing, an increase in
maritime traffic, water pollution, habitat
loss and coastal development.

|
|
|
|
  |
Brain Glia Cells Increase Their DNA
Content to Preserve Vital Blood-Brain
Barrier |
|
The blood-brain barrier is
essential for maintaining the brain's
stable environment -- preventing entry
of harmful viruses and bacteria and
isolating the brain's specific hormonal
and neurotransmitter activity from that
in the rest of the body.

|
|
|
|
  |
Scientists characterize
protein essential to survival of malaria parasite |
|
A biology lab at
Washington University has just cracked the structure
and function of a protein that plays a key role in
the life of a parasite that killed 655,000 people in
2010. The protein is an
enzyme that Plasmodium falciparum, the
protozoan that causes the most lethal form of
malaria, uses to make cell membrane. The protozoan
cannot survive without this enzyme, but even
though the enzyme has many lookalikes in other
organisms, people do not make it. Together these
characteristics make the enzyme an ideal target
for new antimalarial drugs.

|
|
|
|
  |
Backing out
of the nanotunnel |
|
In the world of biomolecules such
as proteins and the hereditary nucleic acids
DNA and RNA, three-dimensional structure
determines function. Analysis of the passage
of such molecules through nanopores offers a
relatively new, but highly promising,
technique for obtaining information about
their spatial conformations.

|
|
|
|
 |
How poor maternal
diet can increase risk of diabetes --
new mechanism discovered |
|
Researchers funded by the
Biotechnology and Biological Sciences
Research Council have shown one way in
which poor nutrition in the womb can put
a person at greater risk of developing
type 2 diabetes and other age-related
diseases in later life. This finding
could lead to new ways of identifying
people who are at a higher risk of
developing these diseases and might open
up targets for treatment.

|
|
|
|
  |
A firmer
understanding of muscle fibrosis |
|
Researchers describe how increased
production of a microRNA promotes
progressive muscle deterioration in a
mouse model of Duchenne muscular
dystrophy (DMD), according to a study
published online on January 2 in the
Journal of Cell Biology (www.jcb.org).

|
|